Drug intelligence / Profile preview

adebrelimab + regorafenib

Development stage: Preclinical
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of adebrelimab, an anti-PD-L1 monoclonal antibody, and regorafenib, an oral multikinase inhibitor. Adebrelimab targets the PD-L1 protein to enhance immune response against cancer cells, while regorafenib inhibits multiple protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment, including VEGFR1-3, TIE2, PDGFR, FGFR, KIT, and RET.

Targets

BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)RAF1 (c-Raf-1 (Y340D/Y341D))NTRK1 (Tropomyosin-related receptor kinase A)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)EPHA2 (Ephrin type-A receptor 2)TEK (Tie2)VEGFR-1 (Vascular endothelial growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)ABL2 (ABL proto-oncogene 2, non-receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)DDR2 (Discoidin domain receptor tyrosine kinase 2)

Beyond the preview

Go deeper on adebrelimab + regorafenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + regorafenib.

Explore the full profile